Heparin Dosing for Left Ventricular Thrombus Treatment
For treating left ventricular thrombus, initiate therapeutic anticoagulation with unfractionated heparin using an 80 U/kg IV bolus followed by 18 U/kg/hour continuous infusion, adjusted to maintain aPTT at 1.5-2 times control (or anti-Factor Xa level 0.3-0.7 U/mL). 1
Initial Dosing Regimen
Intravenous unfractionated heparin (UFH) is the traditional approach for LV thrombus:
- Bolus dose: 80 U/kg IV 2, 1
- Maintenance infusion: 18 U/kg/hour 2, 1
- Target aPTT: 1.5-2.5 times control (approximately 50-70 seconds) 3, 1
- Alternative target: Anti-Factor Xa level 0.3-0.7 U/mL 2, 4, 5
The FDA-approved dosing for therapeutic anticoagulation specifies continuous IV infusion of 20,000-40,000 units/24 hours after a 5,000 unit bolus, though weight-based dosing is preferred for more predictable anticoagulation 1.
Monitoring Protocol
Laboratory monitoring is critical to ensure therapeutic anticoagulation while minimizing bleeding risk:
- Check baseline aPTT, INR, CBC, and platelet count before initiating therapy 6, 1
- Monitor aPTT approximately every 4 hours initially, then at appropriate intervals once therapeutic 1
- Adjust heparin infusion using a validated nomogram to maintain aPTT ratio 1.5-2.5 2, 4, 2
- Monitor platelet counts every 2-3 days for the first 14 days to detect heparin-induced thrombocytopenia 2
- Check hemoglobin/hematocrit at least every 2-3 days initially 6
Alternative Parenteral Options
Low molecular weight heparin (LMWH) is an acceptable alternative with easier administration:
- Enoxaparin: 1 mg/kg subcutaneously every 12 hours 7, 2, 8, 6
- Dalteparin: 200 U/kg subcutaneously once daily for 30 days, then 150 U/kg daily 8, 6
- LMWH offers the advantage of outpatient treatment without routine aPTT monitoring 2, 9
- Exercise caution with creatinine clearance <30 mL/min; enoxaparin requires dose reduction to 1 mg/kg every 24 hours 2, 9, 2
Research evidence specifically for LV thrombus shows high-dose IV heparin (mean 31,291 IU/day) achieved complete thrombus resolution in 83% of patients with mobile/protruding thrombi within 1-3 weeks, with no embolic events 10. A study using enoxaparin 100 IU/kg twice daily demonstrated 73% complete resolution of LV thrombi within 3 weeks 11.
Duration and Transition
Treatment duration for LV thrombus typically extends beyond initial heparinization:
- Continue therapeutic heparin for at least 48 hours, though LV thrombus often requires longer duration 3, 5
- For high-risk thrombi (mobile or protruding), continue until thrombus characteristics improve on serial echocardiography 10, 12
- Transition to oral anticoagulation (warfarin INR 2-3 or DOAC) should overlap heparin for minimum 5 days until INR ≥2.0 for 24 hours 2, 8, 2
Special Considerations
Key clinical caveats when treating LV thrombus:
- Patients with anterior MI and LV thrombus are at particularly high risk for systemic embolization, warranting IV heparin over subcutaneous prophylactic dosing 3, 5
- The risk of heparin-induced thrombocytopenia with UFH may be as high as 5%, making platelet monitoring essential 2
- Avoid intramuscular injections due to hematoma risk 1
- Recent evidence suggests DOACs (rivaroxaban, apixaban) may be alternatives to warfarin for long-term management, though this is still being studied 13, 14, 12
For immediate cardioversion in atrial fibrillation with LV thrombus requiring urgent treatment, administer heparin bolus followed by continuous infusion to prolong aPTT to 1.5-2 times control, then continue oral anticoagulation for at least 4 weeks 15.